2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4489 Longitudinal engagement in survivorship care among childhood leukemia and lymphoma survivors: Single institution experience.

Ksenya Shliakhtsitsava, MD, MAS, Anandini Rao, MD, MS2, Tanya Watt, MD MSc3, Daniel C. Bowers, MD4, Rebecca Eary, DO5, Amy Hughes, PhD6
1 University of Texas Southwestern Medical Center, Dallas, Texas, United States
2 University of Texas Southwestern Medical Center, Dallas, Texas, United States
3 University of Texas Southwestern Medical Center, Dallas, Texas, United States
4 University of Texas Southwestern Medical Center, Dallas, Texas, United States
5 University of Texas Southwestern Medical Center, Dallas, Texas, United States
6 Peter O'Donnell Junior School of Public Health-UT Southwestern, Dallas, Texas, United States, University of Texas Southwestern Medical School, Dallas, Texas, United States

Background: Survivors of childhood leukemia and lymphoma require lifelong risk-based surveillance for treatment-related late effects. However, longitudinal engagement in survivorship care remains incompletely characterized. We evaluated patterns of survivorship care engagement and factors associated with disengagement, with a focus on survivors of childhood hematologic malignancies.

Methods: We conducted a retrospective cohort study of childhood cancer survivors diagnosed at <19 years who attended ≥1 survivorship visit at a large pediatric academic center between 2013 and 2024. Continuity was measured using the Attendance Continuity Score (ACS), defined as the ratio of observed to expected visits based on institutional follow-up protocols. ACS ≥1 was classified as engaged and ACS <1 as disengaged. Demographic, treatment, and late-effect risk data were obtained from an electronic health record–integrated survivorship database. Logistic regression evaluated factors associated with disengagement.

Results: Among 959 eligible survivors, 615 (64.1%) had leukemia or lymphoma, including 501 with leukemia and 114 with lymphoma. Overall, 474 (49.4%) survivors were engaged. Leukemia accounted for 234 (49.4%) engaged and 267 (55.1%) disengaged survivors, whereas lymphoma accounted for 80 (16.9%) and 34 (7.0%), respectively (P=0.008 across diagnostic groups). Compared with leukemia, lymphoma survivors had lower odds of disengagement (OR 0.37, 95% CI 0.24–0.58). This association persisted after adjustment for demographic, clinical, and treatment-related late-effect risk factors (aOR 0.40, 95% CI 0.24–0.65 in the individual late-effect risk model; aOR 0.42, 95% CI 0.26–0.68 in the overall risk model). Increasing age at first survivorship visit was associated with lower odds of disengagement (aOR 0.92 per year), while non-Hispanic Black survivors had higher odds of disengagement (aOR 1.77–1.87). Hispanic ethnicity and Spanish language were not independently associated with disengagement. 

Conclusions: Longitudinal survivorship care engagement differed by hematologic malignancy diagnosis. Lymphoma survivors had substantially lower odds of disengagement than leukemia survivors, even after accounting for demographic, clinical, and treatment-related risk factors. These findings identify childhood leukemia survivors as a population warranting further study to understand diagnosis-specific barriers to sustained survivorship care and inform targeted interventions to support lifelong follow-up.

Ksenya Shliakhtsitsava, MD, MAS: No relevant conflicts of interest to declare.